Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. 2015

Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. migita@nagasaki-mc.com.

BACKGROUND In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. BACKGROUND University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
August 2013, Annals of the rheumatic diseases,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
May 2016, BMC musculoskeletal disorders,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
January 2005, Drugs,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
October 2018, Clinical immunology (Orlando, Fla.),
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
October 2003, Arthritis and rheumatism,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
March 2016, Joint bone spine,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
January 2006, Expert opinion on pharmacotherapy,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
January 1980, Transactions - American Society for Artificial Internal Organs,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
August 1980, The Journal of laboratory and clinical medicine,
Kiyoshi Migita, and Yukihiro Akeda, and Manabu Akazawa, and Shigeto Tohma, and Fuminori Hirano, and Haruko Ideguchi, and Ryutaro Matsumura, and Eiichi Suematsu, and Tomoya Miyamura, and Shunsuke Mori, and Takahiro Fukui, and Yasumori Izumi, and Nozomi Iwanaga, and Hiroshi Tsutani, and Kouichirou Saisyo, and Takao Yamanaka, and Shiro Ohshima, and Takao Sugiyama, and Yojiro Kawabe, and Masao Katayama, and Yasuo Suenaga, and Akira Okamoto, and Hisaji Ohshima, and Yasumasa Okada, and Kenji Ichikawa, and Shigeru Yoshizawa, and Kenji Kawakami, and Toshihiro Matsui, and Hiroshi Furukawa, and Kazunori Oishi
January 2012, Reumatologia clinica,
Copied contents to your clipboard!